Abstract. Adrenomedullin (AM) is a pivotal endogenous vasoactive peptide, which can maintain epithelial barrier function in inflammatory bowel disease. Myosin light chain kinase (MLCK)-dependent phosphorylated myosin light chain kinase (p-MLC) is a key regulator of intestinal barrier function. The aim of the present study was to investigate the effect and mechanism of AM on the intestinal epithelial barrier in a rat model of ulcerative colitis (UC) induced by 2,4,6-trinitro-benzene-sulfonic acid (TNBS). A total of 21 male Sprague-Dawley rats were randomly divided into the following three groups and administered different agents for 7 days: The normal group (water and saline), model group (TNBS and saline) and the AM group (TNBS and AM; 1.0 µg). The weight of rats was recorded every day. Serum tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) levels were detected using ELISA kits. Colon tissue was collected for the assessment of histological alterations. The protein expression of MLCK, p-MLC and zonula occludens-1 (ZO-1) was examined by western blot analysis. Intestinal epithelial tight junctions were examined using transmission electron microscopy. The results demonstrated that in colitis model rats, the expression of TNF-α, IL-6, MLCK and p-MLC significantly increased compared with normal rats. In addition, the expression of ZO-1 decreased (P<0.05) and intestinal epithelial cell permeability increased. Following AM administration, TNF-α, IL-6, MLCK and p-MLC expression significantly decreased compared with the model rats, the expression of ZO-1 increased (P<0.05) and intestinal epithelial cell permeability reduced. These data indicate a protective effect of AM on intestinal epithelial barrier dysfunction via suppression of inflammatory cytokines and downregulation of MLCK-p-MLC in TNBS-induced UC. In conclusion, AM/MLCK-p-MLC may be an important signaling pathway in the occurrence and development of UC.
Introduction
Ulcerative colitis (UC) is an important type of inflammatory bowel disease (IBD), which is a chronic non-specific autoimmune disease. Although environmental factors, infections and immunological and psychological factors can lead to the occurrence of the disease, the specific pathogenesis remains to be elucidated.
Intestinal mucosal barrier damage has been recognized as one of the key factors in the pathogenesis of IBD. A single layer of epithelial cells covering the intestinal mucosal surface, form a physical barrier to withstand external stimuli and infections and maintain homeostasis between the intestinal cavity and internal tissues (1, 2) . The function of intestinal mucosal barrier protection is often referred to as intestinal permeability in IBD (3) . Hyperactivity and increased permeability of intestinal epithelium is an important characteristic of IBD (4) . A previous study confirmed that colonic epithelial barrier dysfunction is considered to be important in the initiation of intestinal inflammation (5) . The main functional characteristic of intestinal epithelial barrier dysfunction is intestinal permeability alterations, which not only easily lead to disease, but may also be an important reason for the onset of delayed healing (6, 7) .
Barrier function is dynamic and can be adjusted by a variety of physiological and pathophysiological stimuli (8) . Several lines of evidence support the theory that myosin light chain kinase (MLCK)-dependent phosphorylation of MLC has a central role in the pathogenesis of IBD (9) (10) (11) . The levels of MLCK are positively associated with disease severity in UC. Increased MLCK expression can lead to the destruction of tight junctions (TJs), which is associated with increased intestinal permeability (12) . This phenomenon can be prevented by MLCK inhibitors (13) .
Adrenomedullin (AM) is an endogenous vasoactive peptide, which is closely associated with cell metabolism, immune function and endocrine and cardiovascular function, and is important in a number of tissues and organs (14) . Previous studies have suggested that intestinal epithelial cells may be an important target for the protective effect of AM. Sakata et al found that AM had a higher expression in the cecum and colon and may have an important protective role in the colon (15) , however, the specific mechanisms involved remain to be elucidated. Prior studies have demonstrated that AM may exert a protective effect in the gut by its anti-inflammatory properties and by suppressing the generation of bacteria (16) (17) (18) . Other studies also suggest that AM can maintain epithelial barrier function via constraining inflammatory cytokine production and altering the balance of T cells (4, (19) (20) (21) . These data indicate that AM is an important protective peptide for intestinal epithelial cells and is important in the protection of the intestinal mucosal barrier. Based on the crucial role of MLCK in the intestinal mucosal barrier, the present study aimed to evaluate the effect of AM on intestinal permeability and on the MLCK-p-MLC pathway in a UC animal model induced by 2,4,6-trinitro-benzene-sulfonic acid (TNBS), and to understand its relative contribution to disease pathogenesis and further clarify the mechanism of AM in the disease process of UC.
Materials and methods
Ethics statement. Animal experiments were approved by the ethics committee of Tongji Medical College Affiliated to Huazhong University of Science and Technology (Wuhan, China) and conformed to the provisions of the Declaration of Helsinki (as revised in Edinburgh 2000). In addition, all animals received humane care and the procedures were performed in accordance with the Principles of Laboratory Animal Care.
Animals.
A total of 21 male Sprague-Dawley rats weighing 200-250 g (Beijing HFK Bioscience Co., Ltd., Beijing, China) were used for the experiments. Rats were maintained at the Animal Experimental Center of Huazhong University of Science and Technology and kept in specific pathogen free air at a temperature of 22˚C with a relative humidity of 50% and a 12 h light and dark cycle. Rats were randomly divided into three groups, namely, the normal, model and AM group, with seven rats in each group.
Introduction of colitis.
Male Sprague-Dawley rats were induced with colitis as previously described (22) . Briefly, rats were fasted for 24 h, then TNBS (Sigma-Aldrich, St. Louis, MO, USA; 5%, 0.6 ml) was integrated in ethanol (50%, 0.25 ml) and delivered into the lumen of the colon via a ~15 cm diameter 2.0 mm rubber infusion tube inserted into the rectum to a depth of ~8 cm from the anal verge.
Administration of AM. The recombinant AM used in the present study was purchased from Sino Biological Inc. (Beijing, China). After 48 h of TNBS administration, AM (1.0 µg of AM diluted in 1.0 ml of saline) was delivered into the lumen of the colon via a 15 cm long rubber infusion tube inserted into the rectum to a depth of ~8 cm from the anal verge. Non AM-treated rats were administered 1.0 ml of saline without AM. AM and saline were administered once a day for 7 days.
Histological analysis. Colon tissues were fixed in 4% paraformaldehyde and histological alterations were observed by hematoxylin and eosin (H&E) staining in routinely processed paraffin-embedded sections.
ELISA evaluation of TNF-α and IL-6. Blood samples were acquired by cardiac puncture and used for the evaluation of ELISA. ELISA for TNF-α (rat TNF-α ELISA kit, cat. no. ERC102a; NeoBioscience, Shenzhen, China) and IL-6 (rat IL-6 ELISA kit, cat. no. ERC003; NeoBioscience) was performed according to the manufacturer's instructions. The peroxidase reaction was terminated by the addition of 100 µl 1 N H 2 SO 4 . The absorbance was examined using a microplate reader (synergy 2; BioTek Instruments, Inc., Winooski, VT, USA) at 450 nm.
Western blot analysis. Monoclonal rabbit anti-MLCK antibody (cat. no. ab76092; Abcam, Cambridge, MA, USA) and polyclonal rabbit anti-myosin light chain (phospho S20) antibody (cat. no. ab2480; Abcam) were used to assess the expression of MLCK and p-MLC. Monoclonal rat anti-ZO-1 antibody (cat. no. MABT11; Millipore, Billerica, MA, USA) was used to assess ZO-1 expression. Proteins were extracted from intestinal mucosa. Total protein (50 µg) from each sample was detected by sodium dodecyl sulfate polyacrylamide gel electrophoresis, respectively. Subsequently, the gels were transferred onto polyvinylidene difluoride membranes (Millipore), which were later blocked in Tris-buffered saline Tween-20 containing 5% fat-free dry milk for 2 h or overnight at room temperature. The blots were performed using primary antibodies against rat MLCK (diluted 1:1,000), rat p-MLCK (diluted 1:1,000) and rat ZO-1 (diluted 1:1,000), respectively, followed by incubation with horseradish peroxidase-linked goat anti-rabbit (diluted 1:10,000; cat. no. LK2001; Tianjin Sungene Biotech Co., Ltd., Tianjin, China) or rabbit anti-rat (1:50,000; cat. no. BA1058; Wuhan Boster Biological Technology, Ltd., Wuhan, China) secondary antibodies. Finally, the extended signals of protein-antibody complexes were detected through exposure to X-ray film. To standardize the protein expression, β-actin was conducted by immunoblotting techniques as an internal control, respectively. BandScan 5.0 software (Glyko Inc., Novato, CA, USA) was used to analyze the gray scale values for different bands.
Measurement of transmission electron microscopy (TEM).
The integrity of the Tjs of epithelial cells was assessed by measuring TEM. The rats were sacrificed by intraperitoneal injection of 0.3 ml/100 g 10% chloral hydrate (Wuhan Union Hospital Pharmacy, Wuhan, China), and then ~1 cm square colon tissue was obtained using a sharp blade. The colon tissue was fixed in 2.5% glutaraldehyde-buffered fixative (absolutely avoid extrusion or using scissors or forceps to uptake) and pre-fixed for 5-10 min. The bowel was then cut into an area of 1x1 mm tissue, fixed in 2.5% glutaraldehyde-buffered fixative for 2-4 h, using 0.1 M phosphate buffer (pH 7.4) and washed twice, for 20 min each. The tissue was then postfixed in 1% osmium tetroxide for 2 h, dehydrated in acetone, and embedded in epoxy resin 618.
Areas of interest were selected from semi-thin sections, which were initally stained with aqueous uranyl acetate followed by lead citrate. The sections were then detected under TEM (VEGA3 LMU; Tescan, Brno, Czekh Republic).
Statistical analysis.
Experiments were duplicated at least three times and the values are presented as the mean ± standard deviation. One-way analysis of variance was used to analyze the statistical differences. Statistical analysis was performed using SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results
Symptoms of rats in different groups. The activity, diet, stool traits, and body weight of each rat were observed. Rats administered TNBS exhibited bradykinesia, reduced food intake, sustained weight loss, and their stools contained blood and mucus, as compared with the normal rats. Conversely, the effects of TNBS were markedly ameliorated in the AM-treated rats, and the reduced body weight of the rats was also improved, as compared with the untreated group (Fig. 1) .
Histological variations. Histological examination demonstrated a normal morphology in normal rats ( Fig. 2A) . However, apparent effusion and adhesion, a shorter bowel length and a thinner intestinal wall was observed in the model group, and a section of the colon revealed superficial ulcers, bleeding and erosion in the mucosa (Fig. 2B) . By contrast, following AM administration pathological alterations were significantly less severe than in the model group and the superficial ulcers of intestinal mucosa were significantly reduced (Fig. 2C) . H&E staining demonstrated mucosal atrophy, partial microvilli loss, edema of the lamina propria and marked inflammatory cell infiltration in the TNBS-induced group (Fig. 3A) compared with the normal group, which exhibited a clear intestinal wall structure and regularly arranged microvilli (Fig. 3B) . Edema and inflammatory cell infiltration were reduced following AM administration (Fig. 3C) .
TNF-α and IL-6. ELISA was used to detect the expression of TNF-α and IL-6. The results demonstrated that the expression of TNF-α and IL-6 in the serum of model rats was significantly higher than in the normal group (P<0.05), whereas a lower expression was observed following AM treatment compared with the model group (P<0.05; Fig. 4 ).
MLCK and p-MLC protein.
MLC has a crucial role in barrier function, an increase in the phosphorylation of MLC can mediate epithelial barrier dysfunction. The present study therefore assessed the effect of AM on MLC phosphorylation using western blot analysis. As shown in Fig. 5 , MLCK and p-MLC expression significantly increased in the model group compared with normal rats ( * P<0.05). However, following AM administration, MLCK and p-MLC expression significantly decreased compared with the untreated colitis rats (P<0.05; Fig. 5 ).
ZO-1 expression.
The TJ is also involved in intestinal mucosal barrier damage. In order to observe alterations in TJ proteins, the present study used western blot analysis to detect the expression level of ZO-1. Western blot analysis demonstrated a decreased expression of ZO-1 in model rats, however, the expression of ZO-1 was decreased in the AM-treated group (Fig. 6) .
TEM of TJs.
Microvilli damage and TJ destruction are major contributors to epithelial dysfunction. In our experiments, TEM demonstrated the integrity of epithelial TJs and neat arrangement of microvilli in the normal group (Fig. 7A) , however, a widened or fractured TJ, sparse microvilli and expansion of endoplasmic reticulum was observed in the model group (Fig. 7B ). These were improved significantly following AM treatment (Fig. 7C) . 
Discussion
IBD, including UC and Crohn's disease affects a large number of individuals. However, the specific mechanism involved remains to be elucidated. One important factor is intestinal mucosal barrier damage, which is often referred to as increased intestinal permeability (1,2) . There are different degrees of intestinal mucosal barrier dysfunction in a variety of IBDs and bacterial dysentery. The integrity of the intestinal epithelial barrier has an important function to prevent electrolyte loss and toxin penetration (23) . Inflammatory cytokines can alter the structure of intestinal epithelial TJs, resulting in impaired epithelial barrier function (24, 25) . During the pathogenesis of IBD, TNF-α has been widely recognized as one of the key proinflammatory cytokines, which can increase paracellular permeability, damage the mucosal barrier and mediate intestinal inflammation, while TNF-α antagonist therapy can effectively alleviate intestinal inflammation and repair the intestinal mucosa tissues (26) . TNF-α may be directly involved in intestinal barrier function damage. Previous studies have demonstrated that the dysfunction of intestinal epithelial cells induced by TNF-α requires the involvement of MLCK and p-MLC, while inhibiting the synthesis of MLCK can significantly reduce the permeability of the epithelial barrier (9, 27, 28) , disclosing a key role of the MLCK-p-MLC pathway in intestinal epithelial barrier dysfunction induced by TNF-α. In rat colitis induced by TNBS, an increased level of TNF-α was detected in the serum, at the same time, the protein expression levels of MLCK and p-MLC were also upregulated, however, this was prevented by the administration of AM, indicating its ability to inhibit activation of the MLCK-p-MLC pathway by TNF-α.
In addition to TNF-α, whether other cytokines are involved in the destruction of the gut barrier, remains to be elucidated. In the present study, serum IL-6 expression correlated with the increase of intestinal epithelial permeability in UC rats induced by TNBS. This result is also in agreement with a previous study demonstrating that IL-6 has a detrimental role in DSS-induced colitis (29) . Notably, IL-6 may also be involved in the destruction of intestinal barrier function, demonstrating that AM may antagonize activation of the MLCK-p-MLC pathway by inhibiting expression of pro-inflammatory cytokines, including TNF-α and IL-6.
The intestinal mucosal barrier is important in maintaining intestinal function (30, 31) . Previous studies have demonstrated that TNF-α can induce intestinal barrier dysfunction and the mechanism may be associated with the upregulation of MLCK expression (32) . Turner et al (1, 33) demonstrated that TNF-α-induced barrier dysfunction requires myosin II activation by MLCK-dependent MLC phosphorylation. Therefore, TNF-α can induce MLC phosphorylation and p-MLC has a crucial role in TNF-α-induced barrier disruption. MLCK is a protein that catalyzes the phosphorylation of MLC, and the expression of MLCK was consistent with p-MLC. Our data revealed that MLCK and p-MLC expression significantly increased compared with normal rats. Notably, ZO-1 protein expression clearly decreased and intestinal epithelial cell permeability increased at the same time. The MLCK-p-MLC pathway is not only essential for mucosal damage, but also causes epithelial barrier damage possibly through controlling the permeability of TJs.
AM is a type of endogenous vasoactive peptide, which is upregulated during inflammation in numerous areas (14, 34) . In the treatment of IBD, AM has been confirmed to have a beneficial effect on the intestine by its anti-inflammatory and antibacterial properties and by suppressing inflammatory cytokines (17) (18) (19) . In an intestinal ischemia-reperfusion injury rat model, AM was demonstrated to have a protective effect on intestinal mucosal structure and function (35) . However, the effect of AM on MLCK and p-MLC of UC rats has not been reported. In our experimental colitis model induced by TNBS, the expression of TNF-α, IL-6, MLCK and p-MLC significantly increased compared with normal rats. AM can decrease the level of TNF-α and IL-6, downregulate the expression of MLCK, inhibit the phosphorylation of MLC and improve the epithelial TJ so as to reduce intestinal mucosal permeability, indicating that AM possibly improves the permeability of the intestinal mucosa by inhibiting the expression of pro-inflammatory cytokines and reducing MLCK and p-MLC levels. Due to the complexity of the signaling pathway, only the MLCK-P-MLC pathway, which is closely associated with colonic mucosa permeability, was examined in the present study. Whether AM can mediate intestinal barrier dysfunction via other molecules, will be further investigated in subsequent experiments.
In conclusion, the current study demonstrated that AM treatment can improve intestinal mucosa permeability by downregulating the expression of proinflammatory cytokines and inhibiting activation of the MLCK-p-MLC pathway so as to ameliorate intestinal barrier function. The suppressive effects of AM on p-MLC may represent a mechanism responsible for the beneficial effects of AM. These findings further explain the pathogenesis of UC and may provide a new therapeutic strategy for the treatment of UC.
